Search

Search Constraints

You searched for: Author/Creator Calvo, Inmaculada

Search Results

1. A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: 2‐Year Data From CHERISH. Issue 11 (March 2014)

2. A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: 2‐Year Data From CHERISH. Issue Volume 66:Issue(2014)supplement 3 (March 2014)

3. A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2‐Year Results From the TENDER Trial. Issue 11 (March 2014)

4. A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2‐Year Results From the TENDER Trial. Issue Volume 66:Issue(2014)supplement 3 (March 2014)

5. AB1072B THE CONSEQUENCES OF THE PROVISIONAL PAEDIATRIC RHEUMATOLOGY INTERNATIONAL TRIALS ORGANISATION JUVENILE IDIOPATHIC ARTHRITIS CLASSIFICATION CRITERIA. (June 2019)

6. Anti–Interleukin‐6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis–Associated Uveitis Refractory to Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty‐Five Patients. Issue 3 (March 2017)

7. Anti–Interleukin‐6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis–Associated Uveitis Refractory to Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty‐Five Patients. Issue 3 (27th February 2017)

8. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Issue 6 (16th May 2014)

9. FRI0181 THE PLUTO STUDY: INTRAVENOUS BELIMUMAB IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS. (June 2019)

10. FRI0555 INFLUENCE OF ANTI-TUMORNECROSIS FACTOR (TNF) DRUG IMMUNOGENICITY ON THE TREATMENT EFFECTIVENESS IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) USING SERUM CALPROTECTIN AS A DISEASE ACTIVITY MARKER. MULTICENTER STUDY. ITACA STUDY. (June 2019)